Back to today’s briefing

Story perspectives

$812 Million Alliance to Revolutionize Obesity Treatments

6/12/2025

50 11

Summary

Story summary

Denmark's Novo Nordisk and US-based Deep Apple Therapeutics have joined forces in an impressive $812 million deal to tackle cardiometabolic diseases, including obesity. Deep Apple will leverage cutting-edge technology to discover new compounds, while Novo Nordisk will spearhead clinical trials and commercialization, aiming to revolutionize treatment options beyond existing therapies.

1 of 1

Story summary

Denmark's Novo Nordisk and US-based Deep Apple Therapeutics have joined forces in an impressive $812 million deal to tackle cardiometabolic diseases, including obesity. Deep Apple will leverage cutting-edge technology to discover new compounds, while Novo Nordisk will spearhead clinical trials and commercialization, aiming to revolutionize treatment options beyond existing therapies.